Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Prospective, Randomized, Multicenter Study Investigating Clinical Efficacy and Safety of the Human Normal Immunoglobulin for Intravenous Administration BT595 in Patients With Chronic Primary Immune Thrombocytopenia (ITP)

NCT02859909 is registered in ClinicalTrials.gov with Biotest as lead sponsor.

NCT NCT02859909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02859909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Prospective, Randomized, Multicenter Study Investigating Clinical Efficacy and Safety of the Human Normal Immunoglobulin for Intravenous Administration BT595 in Patients With Chronic Primary Immune Thrombocytopenia (ITP)
Lead sponsor
Biotest
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2016
Completion date
December 31, 2018
Enrollment
34 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia